CD8A and neoplasm: We performed a meta-analysis of scRNA/TCR-seq data across these published studies (Braun et al., 2021; Krishna et al., 2021; Borcherding et al., 2021), as well as ADAPTeR, evaluating 45 tumor regions from 23 patients, totaling 159,688 cells after filtering for CD8/CD4/Treg cells (see Table S6 for patient, treatment, and sample characteristics; STAR Methods).